Boards

The Supervisory Board is the supervisory committee of the Max Delbrück Center. The Scientific Advisory Board advises the Supervisory Board and the Board of Directors in scientific matters.

Supervisory Board

The Supervisory Board is responsible for monitoring the legality, effectiveness, and economic efficiency of the management of all the activities of the corporation and can request at any time reports from the Board of Directors.

It determines which decisions of the Board of Directors require the prior approval of the Supervisory Board and may issue instructions about important matters involving political aspects of the research and financial affairs of the corporation.

The Supervisory Board consists of no more than twelve members. Its members include, among others: two representatives from the federal government, a representative of the State of Berlin, the chairman of the Scientific Advisory Board, the Presidents of the Humboldt Universität zu Berlin and the Freie Universität Berlin, and two MDC representatives.

Chairperson

Thomas Romes
Federal Ministry of Education and Research

Vice-Chairperson

Dr. Jutta Koch-Unterseher
Senate Department for Higher Education and Research, Health, Long-Term Care and Gender Equality

Members

MinR´in Katrin Benninghoff
Federal Ministry of Education and Research

Prof. Dr. Julia von Blumenthal
President HU Berlin

Prof. Dr. Oliver Daumke
Max Delbrück Center for Molecular Medicine in the Helmholtz Association

Dr. Sabine Gilliam
Pfizer Deutschland

Prof. Dr. Annette Grüters-Kieslich
Charité Campus Virchow Klinikum

Dr. Annette Hammes
Max Delbrück Center for Molecular Medicine in the Helmholtz Association

Prof. Dr. Hannah Monyer
Neurologische Universitätsklinik and Deutsches Krebsforschungszentrum Heidelberg

Christiane Stöhr
Scholz & Friends

Prof. Günter M. Ziegler
Freie Universität Berlin

Scientific Advisory Board

The Scientific Advisory Board advises the Supervisory Board and the Board of Directors in scientific and programmatic, as well as significant structural matters.

The Scientific Advisory Board is responsible for the ongoing evaluation of the results of the research work of the MDC through scientific assessment and is independent in its advisory activity.

The members of the Scientific Advisory Board are up to twelve recognized scientists from Germany or abroad who are close to the main research areas of the MDC.

Chairperson

Prof. Dr. Jo Bury
Vlaams Instituut voor Biotechnologie (VIB), Gent, Belgien

Vice-Chairperson

Prof. Dr. Dietmar Vestweber
Max-Planck-Institut für Molekular Medizin, Münster

Members

Prof. Dr. Ralf Bargou
Onkologisches Zentrum, Universitätsklinikum Würzburg, Würzburg

Prof. Dr. Barbara Casadei
Radcliffe Department of Medicine, University of Oxford, UK

Dr. Jan Ellenberg
The European Molecular Biology Laboratory (EMBL), Heidelberg

Dr. Eileen Furlong
The European Molecular Biology Laboratory (EMBL), Heidelberg

Prof. Dr. Jennifer Lippincott-Schwartz
Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, Virginia, USA

Prof. Dr. Brenda Schulman
Max-Planck-Institut für Biochemie, Martinsried

Dr. Oliver Stegle
DKFZ, Heidelberg

Prof. Dr. Elly Tanaka
Research Institute of Molecular Pathology, Vienna BioCenter, Wien, Österreich

Dr. Gene W. Yeo
University of California San Diego